Glenmark Pharmaceuticals Reports Strong Profit Growth Amid Rising Interest Costs in March 2025
Glenmark Pharmaceuticals has announced its financial results for the quarter ending March 2025, showing significant growth in Profit After Tax at Rs 209.54 crore compared to the previous four quarters. However, the company also faced increased interest expenses, indicating a potential shift in its financial structure.
Glenmark Pharmaceuticals has recently reported its financial results for the quarter ending March 2025, revealing notable developments in its performance metrics. The company's score has undergone an adjustment, reflecting a shift from its previous assessment. In terms of profitability, Glenmark Pharma reported a Profit After Tax (PAT) of Rs 209.54 crore, showcasing a significant growth compared to the average PAT of Rs -43.96 crore from the preceding four quarters. This substantial increase indicates a positive trend in the company's near-term profitability outlook.
Conversely, the company has experienced a rise in interest costs, with quarterly interest expenses reaching Rs 66.71 crore, marking a quarter-on-quarter growth of 27.58%. This uptick in interest expenses suggests an increase in borrowings, which may impact the company's financial structure moving forward.
Overall, Glenmark Pharmaceuticals' recent financial results highlight a mix of positive profitability trends alongside rising interest costs, leading to a revision in its score.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
